Prostatitis treatment

Spivey JM, Cummings DM, Pierson NR. Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy 1996 16(2) 314-16. 

The Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate Treatment comparisons. J Urol 1967 98 516— 522. 

X. Wu, S.J. Dibiase, R. GuUapaUi, G.X. Yu, Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning, Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 1577. 

C,flH2o02- White crystals, m.p. 168-171 °C. Prepared from deoxyanisoin by ethylation, conversion to the alcohol, dehydration and demethylation. It is an oestrogenic substance which is highly active when administered orally. It is used for treating menopausal symptoms, for the suppression of lactation and for treatment of cancer of the prostate. 

The majority of promising drug candidates emerging from marine natural products research to date are potential cancer treatments. Six anti-cancer compounds that are either marine natural products or synthetic analogs of marine natural products have made it to clinical trials. The first of these compounds to enter clinical trials was didemnin B (43), one of a family of cyclic depsipetides isolated from the Caribbean tunicate Trididemnum solidum Didemnin B was advanced to Phase II clinical trials for treatment of small cell lung cancer, myeloma, prostate cancer, and melanoma. Unfortunately, no favorable responses were found so the compound has been withdrawn. Crude extracts of another Caribbean tunicate, Ecteinascidia turbinata, showed extremely... 

Interest contmues in prodrugs of 5-fluorouracil (5-FU) Doxifluridine (8) was recently mtroduced and appears to be more potent and less toxic than 5 FU [10 Flutamide (9) and nilutamide (/O) are both available for the treatment of prostatic cancer [//, 12]... 

N-Heterocycles as drugs for the treatment of benign prostatic hyperplasia 97JMC1293. 

Ornithine decarboxylase is a pyridoxal dependent enzyme. In its catalytic cycle, it normally converts ornithine (7) to putrisine by decarboxylation. If it starts the process with eflornithine instead, the key imine anion (11) produced by decarboxylation can either alkylate the enzyme directly by displacement of either fluorine atom or it can eject a fluorine atom to produce viny-logue 12 which can alkylate the enzyme by conjugate addidon. In either case, 13 results in which the active site of the enzyme is alkylated and unable to continue processing substrate. The net result is a downturn in the synthesis of cellular polyamine production and a decrease in growth rate. Eflornithine is described as being useful in the treatment of benign prostatic hyperplasia, as an antiprotozoal or an antineoplastic substance [3,4]. 

A large and rapidly growing number of clinical trials (phase I and phase II) evaluating the potential of DNA vaccines to treat and prevent a variety of human diseases are currently being performed ( http // clinicaltrials.gov) however, there is yet no licensed DNA vaccine product available for use in humans. The clinical trials include the treatment of various types of cancers (e.g., melanoma, breast, renal, lymphoma, prostate, and pancreas) and also the prevention and therapy of infectious diseases (e.g., HIV/ABDS, malaria, Hepatitis B vims, Influenza vims, and Dengue vims). So far, no principally adverse effects have been reported from these trials. The main challenge for the development of DNA vaccines for use in humans is to improve the rather weak potency. DNA vaccines are already commercially available for veterinary medicine for prevention of West Nile Vims infections in horses and Infectious Hematopoetic Necrosis Vims in Salmon. 

As endothelins mediate potent vasoconstrictor effects, ECE inhibitors and endothelin receptor antagonists were developed for the treatment of cardiovascular diseases, such as acute and chronic heart failure, pulmonary hypertension and subarachnoid haemorrhage. As ETa recqrtors have potent mitogenic responses and may promote progression of ovarian and prostate cancer and bone metastases ETA receptors are also considered as a potential targets for anti-tumour activity. 

In clinical use are pure and partial agonists and antagonists (see individual SHR) as contraceptives, treatment for hormonal ablation in breast and prostate cancer, and HRT in osteoporosis. 

ATC C02CA G04CB01 Use antihypertensive, aj-antagonist, treatment 6f benign prostatic hypertrophy... 

Use synthetic nonapeptidc agonist analog of gonadorelin (LH-RH), gonad stimulating principle for treatment ol hormone sensitive prostatic carcinoma and endometriosis... 

---